Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 20

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 20
---
459,696 ordinary shares subject to options outstanding under the Company’s 2020 Amended and Restated Share Incentive Plan and 2022 Performance Incentive Plan;

•

103,468 ordinary shares available for grant under the Company’s 2022 Performance Incentive Plan;

•

275,000 unvested restricted share units under the Company’s 2022 Performance Incentive Plan;

•

1,345,658 ordinary shares (including ordinary shares represented by ADSs) to be issued upon the exercise of warrants outstanding (including the warrants issued in registered direct offering in August 2025 (the “2025 August RDO”), while excluding the Warrants issued in the 2025 September PIPE); and

•

any ordinary shares (including ordinary shares represented by ADSs) issuable upon exercise of the Warrants, which are registered on the registration statement of which this prospectus forms a part.

Unless otherwise indicated, all information contained in this prospectus assumes (i) no exercise of the outstanding options described above; and (ii) no exercise of the Warrants.

<div align='center'>12</div>

TABLE OF CONTENTS

### RISK FACTORS
Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the section titled “Risk Factors” in our most recent Annual Report on Form 20-F and any subsequent Annual Report on Form 20-F or reports on Form 6-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus and any accompanying prospectus, as updated by our subsequent filings under the Exchange Act, before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.

In the United States and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to sell profitably any product candidates for which we obtain marketing approval.

For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the ACA, is a sweeping law intended to broaden access to health insurance,